# Brain Insulin Resistance in Mood Disorders

> **NCT03915613** · PHASE1,PHASE2 · UNKNOWN · sponsor: **University Health Network, Toronto** · enrollment: 150 (estimated)

## Conditions studied

- Major Depressive Disorder
- Bipolar Disorder
- Anhedonia
- Intranasal Insulin

## Interventions

- **DRUG:** Humulin R
- **DRUG:** Diluent

## Key facts

- **NCT ID:** NCT03915613
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-10-06
- **Primary completion:** 2024-10-05
- **Final completion:** 2024-10-05
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2023-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03915613

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03915613, "Brain Insulin Resistance in Mood Disorders". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03915613. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*